PRESS RELEASE : MorphoSys AG: MorphoSys and I-Mab -2-

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform 
Act of 1995 and other federal securities laws, including statements regarding data from the TJ210/MOR210 phase 1 trial, 
the potential implications of clinical data for patients, and I-Mab's advancement of, and anticipated clinical 
development, regulatory milestones and commercialization of TJ210/MOR210. Actual results may differ materially from 
those indicated in the forward-looking statements as a result of various important factors, including but not limited 
to I-Mab's ability to demonstrate the safety and efficacy of its drug candidates; the clinical results for its drug 
candidates, which may not support further development or NDA/BLA approval; the content and timing of decisions made by 
the relevant regulatory authorities regarding regulatory approval of I-Mab's drug candidates; I-Mab's ability to 
achieve commercial success for its drug candidates, if approved; I-Mab's ability to obtain and maintain protection of 
intellectual property for its technology and drugs; I-Mab's reliance on third parties to conduct drug development, 
manufacturing and other services; I-Mab's limited operating history and I-Mab's ability to obtain additional funding 
for operations and to complete the development and commercialization of its drug candidates; and the impact of the 
COVID-19 pandemic on the Company's clinical development, commercial and other operations, as well as those risks more 
fully discussed in the "Risk Factors" section in I-Mab's most recent annual report on Form 20-F, as well as discussions 
of potential risks, uncertainties, and other important factors in I-Mab's subsequent filings with the U.S. Securities 
and Exchange Commission. All forward-looking statements are based on information currently available to I-Mab, and 
I-Mab undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new 
information, future events or otherwise, except as may be required by law. 
 
Contacts: 
 
MorphoSys 
Media Contacts:                             Investor Contacts: 
Thomas Biegi                                Dr. Julia Neugebauer 
Vice President                              Senior Director 
Tel.: +49 (0)89 / 89927 26079               Tel: +49 (0)89 / 899 27 179 
[e-mail]                  [e-mail] 
Jeanette Bressi                             Myles Clouston 
Director, US Communications                 Senior Director 
Tel: [phone]                        Tel: [phone] 
[e-mail]               [e-mail] 
I-Mab 
Media Contact:               Investor Contact: 
Gigi Feng                    Jielun Zhu 
Chief Communications Officer Chief Financial Officer 
[e-mail] [e-mail] 
[phone]             [phone] ----------------------------------------------------------------------------------------------------------------------- 

2021-01-25 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de -----------------------------------------------------------------------------------------------------------------------

Language:     English 
Company:      MorphoSys AG 
              Semmelweisstr. 7 
              82152 Planegg 
              Germany 
Phone:        [phone] 
Fax:          [phone] 
E-mail:       [e-mail] 
Internet:     www.morphosys.com 
ISIN:         DE0006632003 
WKN:          663200 
Indices:      MDAX, TecDAX 
Listed:       Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, 
              Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange; Nasdaq 
EQS News ID:  1163127 
 
End of News   DGAP News Service 
=------------ 

1163127 2021-01-25

(END) Dow Jones Newswires

January 25, 2021 16:01 ET (21:01 GMT)